US FDA approves Ionis Pharma's therapy to treat rare genetic disorder
03/09/2026 21:02
US FDA approves Ionis Pharma's therapy to treat rare genetic disorder Sept 3 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' IONS.O therapy to treat a rare condition that affects the brain's white matter.
(Reporting by Christy Santhosh in Bengaluru; Editing by Sahal Muhammed)
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study